Low-risk and intermediate-risk acute myeloid leukemia
Conditions
Interventions
autologous transplantation:conditioning
Sponsors
Institute of Hematology and Blood Diseases Hospital,CAMS & PUMC
Eligibility
Sex/Gender
All
Age
12 Years to 65 Years
Inclusion criteria
Inclusion criteria: 1. Low and medium risk AML patients diagnosed by bone marrow cell morphology, immunology and genetics; 2. Aged < 65 years, male or female; 3. One course of induction chemotherapy reaches CRMRD -; 4. The physical condition assessment (ECOG-PS) of the eastern oncology collaboration group was 0-2 points; 5. The informed consent form must be signed before the start of the study procedure. For patients aged 18 years and above, the informed consent form should be signed by the patient himself or his immediate family members. For children and adolescents under the age of 18, the informed consent form should be signed by the legal guardian. Considering the patient's condition, if the patient's signature is not conducive to the treatment of the disease, the legal guardian or the patient's immediate family member shall sign the informed consent form.
Exclusion criteria
Exclusion criteria: 1. Central nervous system leukemia; 2. With extramedullary infiltration; 3. Have a history of other tumors and have received any treatment for this tumor in the past 3 years; 4. Serological reaction of HIV or active hepatitis C virus is known to be positive; 5. Those suffering from mental illness or other conditions cannot cooperate with the requirements of research, treatment and monitoring; 6. Active heart disease is defined as one or more of the following: history of uncontrolled or symptomatic angina pectoris; Myocardial infarction less than 6 months from the time of study; A history of arrhythmias requiring medication or with severe clinical symptoms; Uncontrolled or symptomatic congestive heart failure (>NYHA grade 2); Ejection fraction is lower than the lower limit of the normal range; 7. The researcher thinks it is not suitable for the participants.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| overall survival; | — |
Secondary
| Measure | Time frame |
|---|---|
| disease-free survival;relapse rate;transplant related mortality; | — |
Countries
China
Contacts
Public ContactWang Jianxiang, Jiang Erlie
Institute of Hematology and Blood Diseases Hospital, CAMS & PUMC?
Outcome results
None listed